ClinicalTrials.gg
CompletedNCT04086745RA-BRANCHUpdated Jul 10, 2026Results posted

A Study of Baricitinib in Participants With Rheumatoid Arthritis

A Phase 4 interventional study of Baricitinib and TNF Inhibitor in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 119 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
4th of 23
1,050 · median 290
Started
2020
the only one that year
Phase 4
9 of 23
3 open now
Registered
15th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 4, and was the 15th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have at least one of the following characteristics:

    • Documented evidence of a VTE prior to this study
    • At least 60 years of age
    • A (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or
    • Age 50 to less than 60 years and BMI 25 to less than 30 kg/m²
  • Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drug (DMARD) (synthetic or biologic)

Exclusion criteria

Exclusion Criteria:

  • Participant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was:

    • discontinued for lack or loss of efficacy for RA, or
    • discontinued for intolerance (AE) when used for any indication
  • Participants must not be pregnant or breastfeeding
  • Participants must not have had more than one VTE
  • Participants must not have cancer
  • Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness
  • Participants must not have had a within four weeks of study start
  • Participants must not have participated in any other clinical trial within four weeks of study start
  • Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,050 participants (actual)

Study arms

  • Experimental
    Baricitinib 2mg

    Participants received 2 milligrams (mg) of baricitinib once daily until the planned number of adjudicated primary endpoint events occurred or until the data monitoring committee (DMC) recommended early termination. Those with inadequate response at 1-year after start of treatment with baricitinib 2 mg could receive rescue treatment with baricitinib 4 mg.

    Drug: Baricitinib

  • Experimental
    Baricitinib 4mg

    Participants received 4 mg of baricitinib once daily until the planned number of adjudicated primary endpoint events occurred or until the DMC recommended early termination.

    Drug: Baricitinib

  • Active comparator
    Tumor Necrosis Factor (TNF) Inhibitor

    Participants received a TNF inhibitor (adalimumab or etanercept) administered according to approved local labeling until the planned number of adjudicated primary endpoint events occurred or until the DMC recommended early termination.

    Drug: TNF Inhibitor

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugTNF Inhibitor

    Administered subcutaneously.

    Also known as: Etanercept, Adalimumab

06

What researchers measure

Primary outcomes

  1. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

Secondary outcomes

  1. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  2. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first ATE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  3. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first MACE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  4. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first malignancy (excluding NMSC) was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  5. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first opportunistic infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  6. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first serious infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

Other outcomes

  1. Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor

    Duration of exposure was calculated as: * Baricitinib 2mg exposure = date of last baricitinib 2mg treatment - date of first baricitinib 2mg dose + 1. For participants who were rescued from baricitinib 2 mg to 4 mg, their drug exposure after rescue was censored and not counted as exposure to baricitinib 2mg. * Baricitinib 4mg exposure = date of last baricitinib 4mg treatment - date of first baricitinib 4mg dose + 1. TNF inhibitor exposure = date of last TNFi (adalimumab or etanercept) - date of first TNFi dose (adalimumab or etanercept) + 1, regardless of treatment cycling from adalimumab to etanercept or vice versa. \- Total baricitinib exposure (2/4 mg) = date of last baricitinib (2mg or 4mg) treatment - date of first baricitinib (2mg or 4mg) dose + 1, regardless of rescue from baricitinib 2mg to baricitinib 4mg. Patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

    Time frame: From the date of first dose of study drug up to the last dose (approximately up to 5.3 years)

07

Results

Posted Jul 10, 2026
Limitations and caveats
The treatment was not blinded for the participants, study site personnel, and clinical research associates. This open label design might have introduced some bias, for example in reporting of relatedness of adverse events.

Participant flow

Participant flow — Overall Study
MilestoneBaricitinib 2mgBaricitinib 4mgTumor Necrosis Factor (TNF) Inhibitor
Started352350348
Safety analysis set340333327
Pooled analysis set121912141207
Completed138155151
Not completed214195197
Withdrew: Adverse event202921
Withdrew: Death665
Withdrew: Protocol deviation161514
Withdrew: Withdrawal by subject768469
Withdrew: Physician decision181121
Withdrew: Lack of efficacy321525
Withdrew: Pregnancy100
Withdrew: Participants who were unable to attend their final study visit313
Withdrew: Site terminated by sponsor312
Withdrew: Lost to follow-up292619
Withdrew: Other10718

Outcome measures

PrimaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · Hazard ratio (hr): 1.606 · 95% CI 0.969 to 2.660
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · Hazard ratio (hr): 1.704 · 95% CI 0.943 to 3.079
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · Hazard ratio (hr): 1.688 · 95% CI 0.968 to 2.943
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first ATE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.848 · Hazard ratio (hr): 1.102 · 95% CI 0.408 to 2.980
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.481 · Hazard ratio (hr): 1.365 · 95% CI 0.574 to 3.243
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.737 · Hazard ratio (hr): 1.145 · 95% CI 0.521 to 2.516
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first MACE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.911 · Hazard ratio (hr): 1.038 · 95% CI 0.542 to 1.987
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.519 · Hazard ratio (hr): 1.204 · 95% CI 0.685 to 2.116
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.824 · Hazard ratio (hr): 1.059 · 95% CI 0.638 to 1.760
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first malignancy (excluding NMSC) was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.077 · Hazard ratio (hr): 1.526 · 95% CI 0.955 to 2.438
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.572 · Hazard ratio (hr): 1.142 · 95% CI 0.721 to 1.810
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.239 · Hazard ratio (hr): 1.270 · 95% CI 0.853 to 1.890
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first opportunistic infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.998 · Hazard ratio (hr): 0.999 · 95% CI 0.303 to 3.293
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.465 · Hazard ratio (hr): 1.470 · 95% CI 0.523 to 4.132
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.642 · Hazard ratio (hr): 1.252 · 95% CI 0.485 to 3.228
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first serious infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.262 · Hazard ratio (hr): 1.185 · 95% CI 0.881 to 1.593
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.045 · Hazard ratio (hr): 1.320 · 95% CI 1.007 to 1.731
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.022 · Hazard ratio (hr): 1.323 · 95% CI 1.040 to 1.681
Other pre-specifiedTotal Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor

Duration of exposure was calculated as: * Baricitinib 2mg exposure = date of last baricitinib 2mg treatment - date of first baricitinib 2mg dose + 1. For participants who were rescued from baricitinib 2 mg to 4 mg, their drug exposure after rescue was censored and not counted as exposure to baricitinib 2mg. * Baricitinib 4mg exposure = date of last baricitinib 4mg treatment - date of first baricitinib 4mg dose + 1. TNF inhibitor exposure = date of last TNFi (adalimumab or etanercept) - date of first TNFi dose (adalimumab or etanercept) + 1, regardless of treatment cycling from adalimumab to etanercept or vice versa. \- Total baricitinib exposure (2/4 mg) = date of last baricitinib (2mg or 4mg) treatment - date of first baricitinib (2mg or 4mg) dose + 1, regardless of rescue from baricitinib 2mg to baricitinib 4mg. Patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

Time frame:
From the date of first dose of study drug up to the last dose (approximately up to 5.3 years)
Reported as:
Number · patient-years
Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor
patient-yearsBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor622.7648.51289.6672.0

Adverse events

Collected over From the time of the informed consent signature up to the last study visit (approximately up to 5.3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib 2mg6/352 (1.7%)78/340 (22.9%)30/340 (8.8%)
Baricitinib 4mg6/350 (1.7%)79/333 (23.7%)28/333 (8.4%)
TNF Inhibitor5/348 (1.4%)68/327 (20.8%)35/327 (10.7%)
Most frequent serious events
Showing 10 of 227
Most frequent serious events
EventBaricitinib 2mgBaricitinib 4mgTNF Inhibitor
PneumoniaInfections and infestations10/3409/3337/327
Covid-19Infections and infestations8/3409/3333/327
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/822/740/79
Acute kidney injuryRenal and urinary disorders6/3400/3330/327
Deep vein thrombosisVascular disorders3/3404/3335/327
Prostate cancer stage iiNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/821/740/79
Non-cardiac chest painGeneral disorders0/3401/3334/327
CellulitisInfections and infestations1/3400/3334/327
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/3401/3334/327
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/3403/3334/327
Most frequent other events
Most frequent other events
EventBaricitinib 2mgBaricitinib 4mgTNF Inhibitor
Covid-19Infections and infestations30/34028/33335/327

Baseline characteristics

All participants from the safety analysis set.

Age, Continuous
Age, Continuous(years)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Mean59.90 ± 11.5260.80 ± 11.2761.20 ± 10.9060.60 ± 11.24
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Female258259248765
Male827479235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Hispanic or Latino698061210
Not Hispanic or Latino264245257766
Unknown or Not Reported78924
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
American Indian or Alaska Native4239
Asian1449
Native Hawaiian or Other Pacific Islander0000
Black or African American413338112
White287286275848
More than one race25512
Unknown or Not Reported53210
Region of Enrollment
Region of Enrollment(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
United States3403333271000
08

Study locations

119 sites
  • Arizona Research Clinic PLLC
    Chandler, Arizona 85225, United States
  • Arizona Arthritis & Rheumatology Associates, P. C.
    Mesa, Arizona 85202, United States
  • Arizona Arthritis & Rheumatology Research
    Paradise Valley, Arizona 85253, United States
  • Sun Valley Arthritis Center, LTD
    Peoria, Arizona 85381, United States
  • Arizona Arthritis & Rheumatology Associates
    Phoenix, Arizona 85037, United States
  • Arthritis and Rheumatism Associates
    Jonesboro, Arkansas 72401, United States
  • Providence St. Joseph's Medical Center
    Burbank, California 91505, United States
  • Hope Clinical Research, Inc.
    Canoga Park, California 91303, United States
  • Medvin Clinical Research - Covina
    Covina, California 91722, United States
  • TriWest Research Associates LLC
    El Cajon, California 92020, United States
  • Newport Huntington Med Grp
    Huntington Beach, California 92648, United States
  • BioSolutions Clinical Research Center
    La Mesa, California 91942, United States
  • Valerius Medical Group and Research Center of Greater Long Beach
    Los Alamitos, California 90720, United States
  • R. Srinivasan, M.D., Inc. dba Monterey Park Medical Center
    Monterey Park, California 91754, United States
  • ACRC Studies
    Poway, California 92064, United States
  • Desert Medical Advances
    Rancho Mirage, California 92270, United States
  • Purushotham & Akther Kotha MD Inc
    San Diego, California 92120, United States
  • East Bay Rheumatology Medical Group, Inc
    San Leandro, California 94578, United States
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
  • Dan La, MD Inc
    Tujunga, California 91042, United States
  • Office: Dr Robin K Dore
    Tustin, California 92780, United States
  • Inland Rheumatology & Osteoporosis Medical Group
    Upland, California 91786, United States
  • Nazanin Firooz, MD Inc.
    West Hills, California 91307, United States
  • Medvin Clinical Research - Whittier
    Whittier, California 90602, United States
  • Danbury Clinical Research, LLC
    Danbury, Connecticut 06810, United States
  • Delaware Arthritis
    Lewes, Delaware 19958, United States
  • Omega Research Debary, LLC
    DeBary, Florida 32713, United States
  • Cria Center for Rheumatology
    Fort Lauderdale, Florida 33334, United States
  • SIMED Health
    Gainesville, Florida 32607, United States
  • GNP Research at Mark Jaffe, MD
    Hollywood, Florida 33024, United States
  • Rheumatology Center Of Palm Beach, Pllc
    Lake Worth, Florida 33467 2991, United States
  • Arthritis and Rheumatology Center of South Florida
    Margate, Florida 33063, United States
  • Miami Clinical Reserach
    Miami, Florida 33155, United States
  • Felicidad Medical Research
    Miami, Florida 33185, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Heuer MD Research
    Orlando, Florida 32819, United States
  • UCF Health Lake Nona Orlando
    Orlando, Florida 32827, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • BayCare Health System Inc
    St. Petersburg, Florida 33705, United States
  • West Broward Rheumatology Associates
    Tamarac, Florida 33321, United States
  • Avita Clinical Research
    Tampa, Florida 33613, United States
  • Tampa Medical Group, P.A.
    Tampa, Florida 33614, United States
  • Florida Medical Clinic LLC
    Zephyrhills, Florida 33542-7505, United States
  • Arthritis & Rheumatology of Georgia
    Atlanta, Georgia 30342, United States
  • Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • St Luke's Clinic - Intermountain Orthopaedics
    Boise, Idaho 83702, United States
  • Hinsdale Orthopaedics, Illinois Bone and Joint
    Hinsdale, Illinois 60521, United States
  • Rockford Orthopedic Associates
    Rockford, Illinois 61107, United States
  • Orthoillinois
    Rockford, Illinois 61114, United States
  • Greater Chicago Specialty Physicians, LLC
    Schaumburg, Illinois 60195, United States
  • Center of Robert Hozman
    Skokie, Illinois 60076, United States
  • Beacon Medical Group Clinical Research
    South Bend, Indiana 46617, United States
  • Graves-Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Western KY Rheumatology PLLC
    Hopkinsville, Kentucky 42240, United States
  • Accurate Clinical Research
    Lake Charles, Louisiana 70605, United States
  • Arthritis and Diabetes Clinic, Inc.
    Monroe, Louisiana 71203, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • Michigan Rheumatology Group
    Grand Blanc, Michigan 48439, United States
  • Pandit Rheumatology PC
    Okemos, Michigan 48864, United States
  • Jefferson City Medical Group
    Jefferson City, Missouri 65109, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • West County Rheumatology
    St Louis, Missouri 63131, United States
  • Lovelace Scientific Resources
    Henderson, Nevada 89104, United States
  • Allied Clinical Research
    Reno, Nevada 89519, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Arthritis Care Medical Center
    Somerset, New Jersey 08873, United States
  • Atlantic Coastal Research
    Toms River, New Jersey 08757, United States
  • Sahni Rheumatology & Therapy PC
    West Long Branch, New Jersey 07764, United States
  • NYU Langone
    New York, New York 10016, United States
  • Medication Management
    Greensboro, North Carolina 27408, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28601, United States
  • Cape Fear Arthritis Care
    Leland, North Carolina 28451, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Cincinnati Arthritis Associates
    Cincinnati, Ohio 45242, United States
  • Craig S Thompson MD LLC
    Marion, Ohio 43302, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Arthritis & Rheumatology Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73103, United States
  • Good Samaritan Hospital Corvallis
    Corvallis, Oregon 97330, United States
  • Advanced Rheumatology and Arthritis Research Center, PC
    Cranberry Township, Pennsylvania 15090, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Pennsylvania Regional Center for Arthritis and Osteoporosis Research
    Wyomissing, Pennsylvania 19610, United States
  • Articularis Healthcare d/b/a/ Low Country Rheumatology, PA
    North Charleston, South Carolina 29406, United States
  • Monument Health Rapid City Hospital
    Rapid City, South Dakota 57701, United States
  • Cumberland Rheumatology
    Crossville, Tennessee 38555, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Nashville Arthritis and Rheumatology
    Nashville, Tennessee 37203, United States
  • Accent Clinical Research Professionals, LLC
    Allen, Texas 75013, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Arthritis & Osteoporosis Clinic of Brazos Valley
    College Station, Texas 77845, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75235, United States
  • El Paso Integrated Physicians Group, P.A., an Elligo Health Research, Inc. Healthcare Enabled Research Organization
    El Paso, Texas 79912, United States
  • UDL Clinical Research, LLC
    Houston, Texas 77002, United States
  • Pioneer Research Solutions
    Houston, Texas 77008, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Accurate Clinical Management - Houston
    Houston, Texas 77084, United States
  • Synergy Group US
    Katy, Texas 77450, United States
  • Houston Rheumatology & Arthritis Specialists
    Katy, Texas 77494, United States
  • R and H Clinical Research
    Katy, Texas 77494, United States

Showing the first 100 of 119 sites. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in May 2025, 63 months.

Results were first posted in Jul 2026, 1 year 1 month after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 63 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2019
First posted
Sep 12, 2019
StartActual
Feb 14, 2020
Primary completionActual
May 19, 2025
CompletionActual
May 19, 2025
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04086745
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 12, 2019
Start date
Feb 14, 2020
Primary completion
May 19, 2025
Completion
May 19, 2025
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion